These data, therefore, indicate that HDAC blockade could potentially transform PPARγ into a druggable target in endocrine therapy-refractory breast cancer, thus warranting further clinical appraisal of this combinatorial approach. This evidence concerns the gene HDAC9 and breast cancer.